Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25 percent Compared to Placebo in Subjects With Dry Eye (VELOS-3)

Next Previous
X
Search
Trial Profile

A Phase 3, Multicenter, Randomized, Double Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25 percent Compared to Placebo in Subjects With Dry Eye (VELOS-3)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tanfanercept (Primary)
  • Indications Dry eyes
  • Focus Registrational; Therapeutic Use
  • Acronyms VELOS-3
  • Sponsors HanAll Biopharma

    • Most Recent Events

    • 19 Oct 2023 Number of treatment arms increased from 2 to 3 by the addition of Placebo Run-in arm.
    • 19 May 2023 According to a HanAll Biopharma Media Release, company is planning the next study design within 2H2023 and intend to discuss the VELOS-3 data and future plans with the FDA at the earliest opportunity. The study data will be shared at upcoming scientific meetings.
    • 19 May 2023 According to a HanAll Biopharma Media Release, company announced safety and efficacy results of tanfanercept.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top